7 documents found, page 1 of 1
Depressive symptoms and amyloid pathology
Wiels, Wietse A.; Oomens, Julie E.; Engelborghs, Sebastiaan; Baeken, Chris; von Arnim, Christine A.F.; Boada, Mercè; Didic, Mira; Dubois, BrunoImportance: Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology. Objective: To examine the association between depressive symptoms and amyloid pathology and its dependency on age, sex, education...
Neuropsychological contribution to predict conversion to dementia in patients w...
Silva, Dina Lúcia Gomes da; Cardoso, Sandra; Guerreiro, Manuela; Marôco, J. P.; Mendes, Tiago; Alves, Luísa; Nogueira, Joana Maia; Baldeiras, InesDiagnosis of Alzheimer's disease (AD) confirmed by biomarkers allows the patient to make important life decisions. However, doubt about the fleetness of symptoms progression and future cognitive decline remains. Neuropsychological measures were extensively studied in prediction of time to conversion to dementia for mild cognitive impairment (MCI) patients in the absence of biomarker information. Similar neurops...
Neuropsychological contribution to predict conversion to dementia in patients w...
Silva, Dina; Cardoso, Sandra; Guerreiro, Manuela; Maroco, Joao; Mendes, Tiago; Alves, Luisa; Nogueira, Joana; Baldeiras, Ines; Santana, IsabelBackground: Diagnosis of Alzheimer's disease (AD) confirmed by biomarkers allows the patient to make important life decisions. However, doubt about the fleetness of symptoms progression and future cognitive decline remains. Neuropsychological measures were extensively studied in prediction of time to conversion to dementia for mild cognitive impairment (MCI) patients in the absence of biomarker information. Sim...
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE) : a...
van Maurik, Ingrid S; Vos, Stephanie J.; Bos, Isabelle; Bouwman, Femke H; Teunissen, Charlotte E.; Scheltens, Philip; Barkhof, Frederik; Frolich, LutzBackground: Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for treatment when disease-modifying drugs become available. We aimed to establish robust prediction models of disease progression in people at risk of dementia. Methods: In this modelling study, we included people with mild cognitive impairment (MCI) fro...
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a ...
van Maurik, Ingrid S.; Vos, Stephanie J.; Bos, Isabelle; Bouwman, Femke H.; Teunissen, Charlotte E.; Scheitens, Philip; Barkhof, Frederik; Frolich, LutzBackground Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for treatment when disease-modifying drugs become available. We aimed to establish robust prediction models of disease progression in people at risk of dementia. Methods In this modelling study, we included people with mild cognitive impairment (MCI) from ...
The frequency and influence of dementia risk factors in prodromal Alzheimer's d...
Bos, Isabelle; Vos, Stephanie J.; Frölich, Lutz; Kornhuber, Johannes; Wiltfang, Jens; Maier, Wolfgang; Peters, Oliver; Rüther, EckhartWe investigated whether dementia risk factors were associated with prodromal Alzheimer's disease (AD) according to the International Working Group-2 and National Institute of Aging-Alzheimer's Association criteria, and with cognitive decline. A total of 1394 subjects with mild cognitive impairment from 14 different studies were classified according to these research criteria, based on cognitive performance and ...
Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a Eur...
Kruse, Niels; Persson, Staffan; Alcolea, Daniel; Bahl, Justyna M.C.; Baldeiras, Ines; Capello, Elisabetta; Chiasserini, DavideDecreased levels of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) in Parkinson's disease and related synucleinopathies have been reported, however, not consistently in all cross-sectional studies. To test the performance of one recently released human-specific enzyme-linked immunosorbent assay (ELISA) for the quantification of aSyn in CSF, we carried out a round robin trial with 18 participating laborator...